Compare · AVR vs EW
AVR vs EW
Side-by-side comparison of Anteris Technologies Global Corp. (AVR) and Edwards Lifesciences Corporation (EW): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVR and EW operate in Industrial Specialties (Health Care), so they compete in similar markets.
- EW is the larger of the two at $49.45B, about 53.0x AVR ($933.5M).
- Over the past year, AVR is up 169.6% and EW is up 15.5% - AVR leads by 154.1 points.
- AVR has been more active in the news (5 items in the past 4 weeks vs 4 for EW).
- EW has more recent analyst coverage (25 ratings vs 6 for AVR).
- Company
- Anteris Technologies Global Corp.
- Edwards Lifesciences Corporation
- Price
- $10.27+7.09%
- $86.97+1.29%
- Market cap
- $933.5M
- $49.45B
- 1M return
- +14.17%
- +4.52%
- 1Y return
- +169.55%
- +15.50%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 5
- 4
- Recent ratings
- 6
- 25
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest AVR
- Director Moss Gregory S. converted options into 17,580 shares (SEC Form 4)
- Director Roberts David B converted options into 17,580 shares (SEC Form 4)
- Chief Financial Officer Mcdonnell Matthew exercised 62,001 shares at a strike of $6.27 and covered exercise/tax liability with 39,595 shares (SEC Form 4)
- Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance
- Director Knight Susan Elizabeth bought $102,228 worth of shares (11,000 units at $9.29) (SEC Form 4)
- SEC Form 424B3 filed by Anteris Technologies Global Corp.
- Anteris Technologies Global Corp. filed SEC Form 8-K: Financial Statements and Exhibits
- SEC Form 424B5 filed by Anteris Technologies Global Corp.
- SEC Form 3 filed by new insider Knight Susan Elizabeth
- New insider Denaro Stephen claimed ownership of 23,722 shares (SEC Form 3)
Latest EW
- CEO Zovighian Bernard J sold $45,982 worth of shares (523 units at $87.92) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 11-K filed by Edwards Lifesciences Corporation
- SEC Form 11-K filed by Edwards Lifesciences Corporation
- SEC Form 3 filed by new insider Mistras Theodora
- SVP, Corporate Controller Dahl Andrew M. sold $48,853 worth of shares (568 units at $86.08), decreasing direct ownership by 4% to 15,334 units (SEC Form 4)
- CVP,Strategy/Corp Development Bobo Donald E Jr sold $2,000,193 worth of shares (23,145 units at $86.42) (SEC Form 4)
- SEC Form SD filed by Edwards Lifesciences Corporation
- CVP, TMTT & Surgical Chopra Daveen sold $126,905 worth of shares (1,500 units at $84.60), decreasing direct ownership by 3% to 44,324 units (SEC Form 4)
- CVP, TAVR Lippis Daniel J. exercised 620 shares at a strike of $72.68 and sold $50,307 worth of shares (620 units at $81.14) as part of a pre-agreed trading plan (SEC Form 4)
- CVP,Strategy/Corp Development Bobo Donald E Jr sold $1,472,678 worth of shares (17,968 units at $81.96), decreasing direct ownership by 30% to 22,798 units (SEC Form 4)